{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Clinically significant CMV reactivation be determined per the Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum.","groups":[{"description":"Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.\n\nLetermovir: Given PO","id":"OG000","title":"Treatment (Letermovir)"}],"populationDescription":"Data for this outcome was not collected","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Development of CMV Disease","type":"SECONDARY"}